For: | Au KP, Chok KSH. Immunotherapy after liver transplantation: Where are we now? World J Gastrointest Surg 2021; 13(10): 1267-1278 [PMID: 34754394 DOI: 10.4240/wjgs.v13.i10.1267] |
---|---|
URL: | https://www.wjgnet.com/1948-9366/full/v13/i10/1267.htm |
Number | Citing Articles |
1 |
Coskun Ozer Demirtas, Feyza Gunduz. Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story. Journal of Gastrointestinal Cancer 2021; 52(4): 1217 doi: 10.1007/s12029-021-00758-z
|
2 |
Karen Abboud, Godsfavour Umoru, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, Humaid O. Al-Shamsi, Milind Javle, Ashish Saharia, Ashton A. Connor, Sudha Kodali, Rafik M. Ghobrial, Maen Abdelrahim. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers 2023; 15(5): 1433 doi: 10.3390/cancers15051433
|
3 |
Konstantinos Ouranos, Anthi Chatziioannou, Ioannis Goulis, Emmanouil Sinakos. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World Journal of Transplantation 2022; 12(11): 331-346 doi: 10.5500/wjt.v12.i11.331
|
4 |
Saad Alghamdi, Waleed Al-Hamoudi. Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology. Cancers 2023; 15(21): 5115 doi: 10.3390/cancers15215115
|
5 |
Charles-Henri Wassmer, Sofia El Hajji, Xenofon Papazarkadas, Philippe Compagnon, Parissa Tabrizian, Stéphanie Lacotte, Christian Toso. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers 2023; 15(18): 4574 doi: 10.3390/cancers15184574
|
6 |
Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report. American Journal of Transplantation 2024; doi: 10.1016/j.ajt.2024.01.007
|
7 |
Sai Swarupa R Vulasala, Nirmal K Onteddu, Sindhu P Kumar, Chandana Lall, Priya Bhosale, Mayur K Virarkar. Advances and effectiveness of the immunotherapy after liver transplantation. World Journal of Gastrointestinal Surgery 2022; 14(6): 629-631 doi: 10.4240/wjgs.v14.i6.629
|
8 |
Chia Yuen Chong, Michelle S. Goh, Sandro V. Porceddu, Danny Rischin, Annette M. Lim. The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma. American Journal of Clinical Dermatology 2023; 24(1): 25 doi: 10.1007/s40257-022-00742-8
|
9 |
Julian K. Horwitz, Vatche G. Agopian. Indication of Liver Transplant for HCC: Current Status and Future Directions. Current Hepatology Reports 2024; 23(1): 185 doi: 10.1007/s11901-024-00641-y
|
10 |
Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Thomas Talbot, Alessandra Gennari, Mark R. Openshaw, Coskun O. Demirtas, Alessio Cortellini, David J. Pinato. New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. Chemotherapy 2022; 67(3): 164 doi: 10.1159/000521837
|
11 |
Nora Alzahrani, Ayman Al Jurdi, Leonardo V. Riella. Immune checkpoint inhibitors in kidney transplantation. Current Opinion in Organ Transplantation 2023; 28(1): 46 doi: 10.1097/MOT.0000000000001036
|
12 |
Landon L. Chan, Stephen L. Chan. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment. Clinical and Molecular Hepatology 2023; 29(4): 909 doi: 10.3350/cmh.2023.0114
|
13 |
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, Mithun Sharma, Bharat Patodiya, Arif Khan, Sameer Shaik, Ashirwad Pasumarthy, Prateek Chhabra, Pramod Kumar Da, Vivek A. Saraswat, Padaki N. Rao, Duvvur N. Reddy. Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience. Journal of Clinical and Experimental Hepatology 2023; 13(4): 618 doi: 10.1016/j.jceh.2023.02.003
|
14 |
Stefano Kayali, Andrea Pasta, Maria Corina Plaz Torres, Ariel Jaffe, Mario Strazzabosco, Simona Marenco, Edoardo G. Giannini. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2023; 43(1): 8 doi: 10.1111/liv.15419
|
15 |
Kathrine S Rallis, Dimitrios Makrakis, Ioannis A Ziogas, Georgios Tsoulfas. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World Journal of Clinical Oncology 2022; 13(6): 448-472 doi: 10.5306/wjco.v13.i6.448
|
16 |
Stephanie Ji, Hao Liu, Laura Pachella, Ryan D. Stephenson, Roman Groisberg, Sarah A. Weiss. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. Frontiers in Transplantation 2023; 2 doi: 10.3389/frtra.2023.1284740
|
17 |
Anthony C. Bejjani, Richard S. Finn. Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations. Journal of Clinical Oncology 2022; 40(24): 2763 doi: 10.1200/JCO.21.02605
|
18 |
Zurabi Lominadze, Kareen Hill, Mohammed Rifat Shaik, Justin P. Canakis, Mohammad Bourmaf, Cyrus Adams-Mardi, Ameer Abutaleb, Lopa Mishra, Kirti Shetty. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. International Journal of Molecular Sciences 2023; 24(3): 2358 doi: 10.3390/ijms24032358
|